Reaferon-Lipint caps 500000ME #10

Reaferon-Lipint instruction

Reed more about Reaferon-Lipint and buy it on this page

Composition

The composition of one capsule of the drug includes interferon alpha-2b human recombinant 500000 IU - the active substance.
Excipients:
    8.01 mg - sodium chloride;
    4.52 mg of sodium dodecahydrate hydrophosphate;
    0.56 mg of sodium dihydrate phosphate;
    41.18 mg of lipoid C 100;
    4.53 mg - cholesterol;
    91,34 mg - lactose monohydrate;
    0.56 mg - alpha-tocopherol acetate (vitamin E);
    7.54 mg - silicon dioxide colloidal anhydrous.
The shell consists of:
    2% titanium dioxide (E 171) and up to 100% gelatin.

Form of issue

The drug Reaferon-Lipint is available in the form of gelatin capsules with a fine crystalline powder of 500,000 IU of the active substance.
One package contains 10 capsules.

pharmachologic effect

Antiviral and immunomodulating.

Pharmacodynamics and pharmacokinetics

The antiviral effect of the drug Reaferon-Lipint is related to the ability of its active substance, interferon alfa-2b, to be actively involved in the processes of virus reproduction at the cellular level. Possessing influence on specific receptors of the cell membrane, introduces intracellular changes, including the synthesis of specific enzymes (protein kinase and adenylate synthetase) and cytokines, which in turn inhibit the formation of RNA virus and viral protein.
The immunomodulatory effect of the drug is manifested by increased activity of macrophages and "killer" cells, changes in the quantity and quality of cytokines produced, increased functional action of immunocompetent cells, and the modification of secretion and production of intracellular proteins.

Indications for use

Therapy of respiratory viral diseases and influenza in adult patients as part of complex treatment, as well as their prevention during the rise in morbidity and during epidemics.

Contraindications

    patient's age is less than 18 years;
    During pregnancy and breastfeeding;
    lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome;
    individual hypersensitivity to interferon or other components of the drug.

With extreme caution:

    severe myelosuppression;
    renal and / or liver failure.

Side effects

During the application of Reaferon-Lipint capsules, allergic reactions may appear, as well as an influenza-like syndrome including chills, fatigue, fever, lethargy, headache, arthralgia, myalgia, and a decrease in appetite.

Instructions for use (Method and dosage)

Reaferon-Lipint in the form of capsules is recommended for admission to adults and is not suitable for children.
The drug is intended for oral (internal) use 30 minutes before meals.
Capsules are recommended to be swallowed whole and washed down with water.
If you have difficulty swallowing the drug Reaferon-Lipint, the instruction manual allows you to carefully open the capsule and take its contents with a small amount of water.
The daily dose of Reaferon-Lipint in capsules in the treatment of acute respiratory infections and influenza is 1,000,000 IU (2 capsules 500,000 IU per day). The drug is recommended to take in the morning and evening for 5 days.
Prevention of ARVI and influenza is carried out at a dose of 500,000 IU (1 capsule), which is taken 2 times a week. The course of preventive use is 30 days.

Overdose

No cases of an overdose of the drug Reaferon-Lipint were observed. It is theoretically possible to exacerbate dose-dependent side effects. Therapy is symptomatic.

Interaction

Studies have shown the ability of interferon to reduce the activity of P-450 cytochromes, thereby affecting the metabolism of phenytoin, cimetidine, dipyridamole, diazepam, theophylline, warfarin, propranolol and some cytostatics.
Reaferon-Lipint can exacerbate neurotoxic, cardiotoxic, myelotoxic effects in the past of prescribed drugs or drugs used concomitantly with it.
Do not prescribe Reaferon-Lipint together with drugs that depress the central nervous system, as well as with immunosuppressive drugs (including parenteral and oral corticosteroids).

Storage conditions

In the refrigerator at a temperature not exceeding 8 ° C.
Shelf life - 2 years.

special instructions

If allergic reactions occur while taking Reaferon-Lipint, you should consult your doctor.

Children

Capsules of the drug Reaferon-Lipint are not used for children.

With alcohol

Avoid drinking alcoholic beverages during therapy.

In pregnancy and lactation

Not used during pregnancy and lactation.

Reviews about Reaferon-Lipint

In user forums, interferon preparations for the prevention and treatment of ARVI and influenza are consistently receiving positive feedback.
Recall that this drug, due to insufficient research, is not intended for children. Reviews for Reaferon Lipint in capsules, also called erroneously - "Reaferon Lipid", when treating patients of childhood, should be regarded skeptically.